Changes in causes of death and influence of therapeutic improvement over time in patients with heart failure and reduced ejection fraction
Por:
Fernandez-Vazquez, D, Ferrero-Gregori, A, Alvarez-Garcia, J, Gomez-Otero, I, Vazquez, R, Jimenez, JD, Diz, FW, Bardaji, A, Garcia-Pavia, P, Bayes-Genis, A, Gonzalez-Juanatey, JR, Cinca, J, Figal, DAP
Publicada:
1 jul 2020
Resumen:
Introduction and objectives: In patients with heart failure and reduced ejection fraction (HFrEF), several therapies have been proven to reduce mortality in clinical trials. However, there are few data on the effect of the use of evidence-based therapies on causes of death in clinical practice.
Methods: This study included 2351 outpatients with HFrEF (< 40%) from 2 multicenter prospective registries: MUSIC (n = 641, period: 2003-2004) and REDINSCOR I (n = 1710, period: 2007-2011). Variables were recorded at inclusion and all patients were followed-up for 4 years. Causes of death were validated by an independent committee.
Results: Patients in REDINSCOR I more frequently received beta-blockers (85% vs 71%; P < .001), mineralocorticoid antagonists (64% vs 44%; P < .001), implantable cardioverter-defibrillators (19% vs 2%; P < .001), and resynchronization therapy (7.2% vs 4.8%; P = .04). In these patients, sudden cardiac death was less frequent than in those in MUSIC (6.8% vs 11.4%; P < .001). After propensity score matching, we obtained 2 comparable populations differing only in treatments (575 vs 575 patients). In patients in REDINSCOR I, we found a lower risk of total mortality (HR, 0.70; 95%CI, 0.57-0.87; P = .001) and sudden cardiac death (sHR, 0.46; 95%CI, 0.30-0.70; P < .001), and a trend toward lower mortality due to endstage HF (sHR, 0.73; 95%CI, 0.53-1.01; P = .059), without differences in other causes of death (sHR, 1.17; 95% CI, 0.78-1.75; P = .445), regardless of functional class.
Conclusions: In ambulatory patients with HFrEF, implementation of evidence-based therapies was associated with a lower risk of death, mainly due to a significant reduction in sudden cardiac death. (C) 2019 Sociedad Espanola de Cardiologia. Published by Elsevier Espana,S.L.U. All rights reserved.
Filiaciones:
Fernandez-Vazquez, D:
Univ Murcia, Hosp Clin Univ Virgen de la Arrixaca, Serv Cardiol, Murcia, Spain
Ferrero-Gregori, A:
Univ Autonoma Barcelona, Serv Cardiol, Hosp Santa Creu & St Pau, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Alvarez-Garcia, J:
Univ Autonoma Barcelona, Serv Cardiol, Hosp Santa Creu & St Pau, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Gomez-Otero, I:
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Hosp Univ Santiago de Compostela, Serv Cardiol, IDIS, Santiago De Compostela, A Coruna, Spain
Vazquez, R:
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Hosp Univ Puerta del Mar, Serv Cardiol, Cadiz, Spain
Jimenez, JD:
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Hosp Univ 12 Octubre, Fac Med UCM, Serv Cardiol, Madrid, Spain
Diz, FW:
Hosp Arnau Vilanova, Serv Cardiol, IRBLLEIDA, Lleida, Spain
Bardaji, A:
Hosp Univ Joan XXIII, Serv Cardiol, Tarragona, Spain
Garcia-Pavia, P:
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Hosp Univ Puerta de Hierro Majadahonda, Serv Cardiol, Madrid, Spain
Univ Francisco de Vitoria UFV, Fac Med, Madrid, Spain
Bayes-Genis, A:
Hosp Badalona Germans Trias & Pujol, Serv Cardiol, Barcelona, Spain
Gonzalez-Juanatey, JR:
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Hosp Univ Santiago de Compostela, Serv Cardiol, IDIS, Santiago De Compostela, A Coruna, Spain
Cinca, J:
Univ Autonoma Barcelona, Serv Cardiol, Hosp Santa Creu & St Pau, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Figal, DAP:
Univ Murcia, Hosp Clin Univ Virgen de la Arrixaca, Serv Cardiol, Murcia, Spain
Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
Ctr Nacl Invest Cardiovasc CNIC, Madrid, Spain
|